Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody

Elife. 2018 Feb 20;7:e34375. doi: 10.7554/eLife.34375.

Abstract

In amyotrophic lateral sclerosis (ALS) and animal models of ALS, including SOD1-G93A mice, disassembly of the neuromuscular synapse precedes motor neuron loss and is sufficient to cause a decline in motor function that culminates in lethal respiratory paralysis. We treated SOD1-G93A mice with an agonist antibody to MuSK, a receptor tyrosine kinase essential for maintaining neuromuscular synapses, to determine whether increasing muscle retrograde signaling would slow nerve terminal detachment from muscle. The agonist antibody, delivered after disease onset, slowed muscle denervation, promoting motor neuron survival, improving motor system output, and extending the lifespan of SOD1-G93A mice. These findings suggest a novel therapeutic strategy for ALS, using an antibody format with clinical precedence, which targets a pathway essential for maintaining attachment of nerve terminals to muscle.

Keywords: MuSK; agonist antibody; amyotrophic lateral sclerosis; motor neuron; mouse; neurodegeneration; neuromuscular disease; neuroscience.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis / therapy*
  • Animals
  • Antibodies / administration & dosage*
  • Disease Models, Animal
  • Immunologic Factors / administration & dosage*
  • Mice
  • Motor Neurons / drug effects
  • Motor Neurons / physiology
  • Neuromuscular Junction / drug effects*
  • Neuromuscular Junction / physiology*
  • Receptor Protein-Tyrosine Kinases / metabolism*
  • Treatment Outcome

Substances

  • Antibodies
  • Immunologic Factors
  • MuSK protein, mouse
  • Receptor Protein-Tyrosine Kinases